RE: TMAC17 Jan 2023 09:24
For those who aren't aware on what avactas ultimate goal is here:
Tumour microenvironment activated drug conjugates (TMAC®)
Incorporating pre|CISION™ technology in the linker of Affimer-drug conjugates ensures localised, extracellular release of a chemotherapy payload in the tumour microenvironment. This mechanism overcomes the need to target an internalising cancer marker, as with conventional drug conjugates, allowing the Affimer® to be selected to target an immune checkpoint. Thus, the innate immune response to the chemotherapy is supported by the Affimer® immune checkpoint blockade in this novel class of checkpoint targeting tumour microenvironment activated drug conjugates – TMAC®.